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Edited by Judit Ova´diAbstract Podoplanin (Aggrus) is a mucin-type sialoglycopro-
tein that plays a key role in tumor cell-induced platelet aggrega-
tion. Podoplanin possesses a platelet aggregation-stimulating
(PLAG) domain, and Thr52 in the PLAG domain of human
podoplanin is important for its activity. Endogenous or recombi-
nant human podoplanin were puriﬁed, and total glycosylation
proﬁles were surveyed by lectin microarray. Analyses of glyco-
peptides produced by Edman degradation and mass spectrometry
revealed that the disialyl-corel (NeuAca2-3Galbl-3(NeuAca2-
6)GalNAcal-O-Thr) structure was primarily attached to a glyco-
sylation site at residue Thr52. Sialic acid-deﬁcient podoplanin
recovered its activity after additional sialylation. These results
indicated that the sialylated Corel at Thr52 is critical for podopl-
anin-induced platelet aggregation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Disialyl-T1. Introduction
It is well known that tumor metastasis is associated with
platelet-aggregating activity possessed by human and other
mammalian cancer cells [1]. A previous study has clariﬁed that
podoplanin, membranous 44 kDa and 36 kDa sialoglycopro-
teins in cancer cells of mice and humans, respectively, aggre-
gated platelets with no relation to plasma components [2,3].
Podoplanin is known to be a lymphatic speciﬁc marker [4],
and its expression has been reported in many tumor cells [4–
11]. Podoplanin belongs to a type-I transmembrane sialomu-Abbreviations: PLAG, platelet-aggregation-stimulating; CHO, Chinese
hamster ovary; MALDI-TOF-MS, matrix-assisted laser desorption/
ionization time of-ﬂight mass spectrometry; QIT, quadrupole ion trap;
HPLC, high performance liquid chromatography
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doi:10.1016/j.febslet.2006.12.044cin-like glycoprotein that consisted of an extracellular domain
with abundant Ser and Thr residues as potential O-glycosyla-
tion sites, a single transmembrane portion, and a short cyto-
plasmic tail with putative sites for protein kinase C and
cAMP phosphorylation [2,12].
We previously showed that the segment of EDxxVTPG in
the extracellular domain, designated as platelet aggregation-
stimulating (PLAG) domain, was critical for the activity of
podoplanin/Aggrus [2]. In particular, this motif, which is
highly conserved among species, is tandemly triplicated [13].
In the study of targeted mutagenesis to podoplanin molecules,
we obtained evidence that Thr residues of PLAG domain play
an important role for platelet aggregation [2,13]. Furthermore,
unique characteristics of Chinese hamster ovary (CHO)
mutant cell lines, N-glycan-deﬁcient Lecl, CMP-sialic acid
transporter-deﬁcient Lec2, and UDP-galactose transporter-
deﬁcient Lec8, revealed that sialylated O-glycan is critical for
platelet aggregation-inducing activity [14].
In this study, we puriﬁed human podoplanin from a glio-
blastoma cell line LN319 cells and podoplanin-transfected
CHO cells. Using a lectin microarray, Edman degradation,
and matrix-assisted laser desorption/ionization time of-ﬂight
mass spectrometry (MALDI-TOF-MS), it was shown that
podoplanin possesses a disialyl-corel structure at Thr52 in
the PLAG domain, and this structure is critical for its plate-
let-aggregating activity.2. Materials and methods
2.1. Production and puriﬁcation of podoplanin
We previously established FLAG-tagged human podoplanin-trans-
fected CHO and Lec2 cell lines [14]. A glioblastoma cell line LN319,
which expresses endogenous podoplanin, was donated by Dr. Webster
K Cavenee [15]. Cells were lysed with 0.25% Triton X-100 in PBS.
Using anti-FLAG antibody-conjugated agarose gel (M2, Sigma),
podoplanin was puriﬁed from podoplanin-transfected CHO and
Lec2 cells, and eluted using 100 lg/ml FLAG peptide (Sigma). Endog-
enous podoplanin was puriﬁed from LN319 using anti-human
podoplanin antibody (NZ-1) and eluted by hpp38–51 peptide (EGG-
VAMPGAEDDVV) [15].
2.2. Platelet aggregation assay
The platelet aggregation assay was described previously [15]. Brieﬂy,
platelet aggregation was measured by WBA Carna (M.C. Medical)blished by Elsevier B.V. All rights reserved.
332 M.K. Kaneko et al. / FEBS Letters 581 (2007) 331–336with the screen ﬁltration pressure method [16]. Two hundred microli-
ters each of heparinized mouse whole blood samples was pre-incubated
for 2 min, followed by the addition of 12 ll each of puriﬁed protein.
Five minutes later, samples were sucked to detect aggregation pressure.
The ﬁnal platelet aggregation pressure of each reaction tube was deter-
mined at the pressure rate (%) of a pressure sensor connected to the
syringe.
2.3. Lectin microarray
The lectin microarray was basically performed as described by Kuno
et al. [17].
To generate glycan proﬁles for podoplanin, we customized a proce-
dure using the NZ-1 antibody [15]. Interaction of podoplanin with the
lectin immobilized on the glass slide was detected using biotinylated
NZ-l-Cy3-streptoavidin method to proﬁle glycans of podoplanin.
Brieﬂy, puriﬁed podoplanin was diluted to 60 ll with 1% Trition
X-100 in PBS (PBSTx) and applied to the lectin array containing trip-
licate spots of 43 lectin into each of eight-divided incubation baths on
the glass slide (refer to [15]). After incubation at 20 C for 12 h, the
reaction solution was discarded. The glass slide was washed three times
with PBSTx; 60 ll of biotinylated NZ-1 antibody (0.17 lg/ml) in PBS
was applied to the array and then incubated at 20 C for 3 h. After
washing three times with PBSTx, Cy3-labeled streptavidin (GE
Healthcare, UK) was added to the array and then incubated at
20 C for 30 min. The glass slide was rinsed with PBSTx and scanned
using an evanescent-ﬁeld ﬂuorescence scanner (GTMASScan III; Nip-
pon Laser & Electronics Lab, Nagoya, Japan). Lectin binding was
measured by ﬂuorescent intensity.
2.4. Mass spectrometry
Beta-Elimination [18] and permethylation [19] were performed as
described previously. Desialylation was performed at 80 C for 3 h in
2 M acetic acid. MS measurements were carried out using a positive
reﬂectron mode for glycans, and negative reﬂectron mode for glyco-hPod/LN319
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Fig. 1. Puriﬁcation and platelet aggregation assay for endogenous and rec
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LN319, podoplanin-transfected CHO, and podoplanin-transfected Lec2 indu
Carna with the screen ﬁltration pressure method.peptide with a MALDI-TOF mass spectrometer (Reﬂex IV; Bruker-
Daltonik, Germany). All collision-induced dissociation spectra were
acquired with a MALDI-QIT (quadrupole ion trap)-TOF MS spec-
trometer (AXIMA-QIT; Shimadzu, Kyoto, Japan). For each sample
preparation 2,5-DHB was used as the matrix. MSn ﬁngerprint match-
ing was performed as described previously [20].
2.5. Endoproteinase digest, peptide separations, and protein sequencing
Using puriﬁed and concentrated hPod/LN319 and hPod/CHO,
endoproteinase Asp-N digestion was performed in 50 mM Tris–HCl
(pH 8.0) at 37 C for 8 h. The digests were separated by reverse phase
chromatography with a CAPCELLPAC C18 UG120 column (SHISE-
IDO) using high performance liquid chromatography (HPLC, Shima-
dzu). A linear gradient (0–50%) of acetonitrile in 0.1% triﬂuoroacetic
acid was performed at 40 C. The glycosylation site on podoplanin
was determined by Edman microsequencing (PPSQ-23A, Shimazu),
since phenylthiohydantoin derivatives of glycosylated-Thr were not
detected.
2.6. Addition of sialic acid
Sialylation experiments were described previously [21,22]. For the
preparation of hPod/Lec2 with the sialyl Corel (NueAca2-3Galbl-
3GalNAcal-) residue, 25 mM HEPES buﬀer (pH 7.0) containing
30 ll of acceptor substrate (1.0 mg/ml), 10 mM MnCl2 and an appro-
priate concentration of CMP-NeuAc was used. Ninety microliters of
puriﬁed ST3GalI enzyme was added to the reaction mixture and incu-
bated at 37 C for 20 h. For the preparation of hPod/Lec2 with the
disialyl-corel (NueAca2-3Galbl-3(NeuAca2-6)GalNAcal-) residue, ali-
quots of supernatants of the former reaction solution were used as the
acceptor substrate for the next sialylation. An appropriate concentra-
tion of CMP-NeuAc and the puriﬁed ST6GalNAcI enzyme were added
to 30 ll of supernatants and incubated at 37 C for 20 h. Control
hPod/Lec2 sample was also treated in the same experimental condition
except for the addition of ST3GalI or ST6GalNAcI.d/CHO
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3.1. Puriﬁcation of human podoplanin and platelet aggregation
assay
Puriﬁcations of endogenous or recombinant podoplanin
from LN319, podoplanin-transfected CHO, and podoplanin-
transfected Lec2 were achieved by a one-step procedure using
immunoaﬃnity chromatography utilizing a monoclonal anti-
body (NZ-1 [15] or M2). Puriﬁed podoplanin proteins (hPod/
LN319, hPod/CHO, and hPod/Lec2) were conﬁrmed to be
more than 95% pure based on CBB staining (Fig. 1A). All
puriﬁed podoplanins induced platelet aggregation in a dose-
dependent manner (Fig. 1B). In our previous study, we indi-
cated that human podoplanin possessed the ability to induce
aggregation of human and mouse platelets [2]. Furthermore,
platelet aggregation induced by human podoplanin using
mouse platelet was reported to be stronger than one using hu-
man platelet. Therefore, we used mouse platelet in this whole
study. We have investigated the platelet aggregation induced
by podoplanin using both a turbidimetric method with plate-
let-rich plasma (PRP) and a ﬁltration pressure method with
whole blood, and obtained the compatible results using both
methods (data not shown). Lec2 cells are CMP-sialic acid
transporter-deﬁcient in which both glycoproteins and glycolip-
ids lack 90% of sialic acids (SA) [23]. hPod/Lec2 possessed a
trace amount of SA on the puriﬁed protein (Fig. 2). Therefore,
hPod/Lec2 protein could induce platelet aggregation when it
was puriﬁed and concentrated.Fig. 2. Determination of total glycan structure for endogenous and
recombinant podoplanin. Glycan proﬁles of puriﬁed podoplanins from
LN319, podoplanin-transfected CHO, and podoplanin-transfected
Lec2 cells using lectin microarray. The ﬂuorescent intensities of each
lectin on lectin array are indicated with bars. Lectin binding speciﬁc-
ities were as follows: BPL; Galb1-3GlaNAc, TJA-II; b-GalNAc, ABA:
Galb1-3GlaNAca-Thr/Ser (T) and sialyl-T, STL; (GlcNAc)n, Jacalin;
Galb1-3GlaNAca-Thr/Ser and GlaNAca-Thr/Ser, PNA Galb1-3Gal-
NAca-Thr/Ser, WFA; terminal GalNAc, ACA; Galb1-3GalNAca-
Thr/Ser, MPA; Galb1-3GlaNAca-Thr/Ser and GlaNAca-Thr/Ser,
HPA; terminal GalNAc,VVA; terminal GalNAc and GlaNAca-Thr/
Ser, SBA; terminal GalNAc, MAH; Siaa2-3Galb1–3 (Siaa2–6)Gal-
NAca-R, WGA; (GlcNAc)n and multivalent Sia.3.2. Total glycan proﬁling of podoplanin of CHO and LN319
using lectin microarray
We investigated the total glycan proﬁle of hPod/LN319,
hPod/CHO, and hPod/Lec2 using a lectin microarray with
the detection method by biotinylated NZ-1 antibody and
Cy3-labeled streptavidin [15]. Lectin binding was measured
by ﬂuorescent intensity. As shown in Fig. 2, both hPod/
LN319 and hPod/CHO reacted strongly with corel ± sialic acid
binders (ABA, Jacalin, ACA, and MPA) and sialo-mucin
binders (MAH and WGA), but did not react with corel binders
(BPL and PNA). These results indicated that podoplanin on
LN319 or podoplanin-transfected CHO possesses a disialyl-
and/or monosialyl-corel structure. Predictably, hPod/Lec2
reacted intensely to corel binders (BPL and PNA). Residual
sialic acid of hPod/Lec2 was detected by WGA. In particular,
Jacalin and MPA reactivity of hPod/CHO diﬀered from that of
hPod/LN319. Jacalin did not bind to disialyl-corel structure
[24]. Accordingly, these results suggested that hPod/LN319
contains more disialyl-corel compared to hPod/CHO.3.3. Glycan analysis of podoplanin of CHO and LN319 using
mass spectrometry
Next, the total glycans of hPod/LN319 and hPod/CHO were
analyzed by mass spectrometry. Glycans were released from
hPods by reductive b-elimination [18]. The resulting alditols
were permethylated [19] and analyzed with MALDI-TOF
and MALDI-QIT-TOF mass spectrometers. MS spectra
revealed that hPod/CHO bears nearly equal amounts of
(NeuAc)2-Hex-HexNAc-ol (m/z 1257) and NeuAc-Hex-Hex-
NAc-ol (m/z 895), whereas hPod/LN319 bears mainly
(NeuAc)2-Hex-HexNAc-ol (Fig. 3A). In the MS/MS spectrum
of m/z 1257, the signals of m/z 620 and 659, which could beassigned as [permethylated NeuAc-Hex + Na]+ and [permethy-
lated NeuAc-HexNAc-ol + Na]+, were observed (Fig. 3B). All
of these results indicated that the glycans found on podopla-
nin, in LN319 and podoplanin-transfected CHO, are mixture
of monosialyl- and disialyl-corel structures.
3.4. Glycosylation site of functional podoplanin
Mutation of threonine residues in the PLAG domain (52th
threonine (Thr52) of human podoplanin) abolished the platelet
aggregation-inducing abilities [2]. Furthermore, Thr52 was
predicted as a O-glycosylated site [13]. In this study, glycopep-
tides from hPod/LN319 and hPod/CHO digested by Asp-N
were fractionated by HPLC, followed by peptide sequencing,
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Fig. 3. The glycan structure of podoplanin analyzed by mass spectrometry. (A) MS spectra of permethylated alditols released from puriﬁed hPods/
LN319 and hPods/CHO. M/z 895.68: NeuAc-Hex-HexNAc-ol, 1256.81: (NeuAc)2-Hex-HexNAc-ol. (B) MS/MS spectrum of m/z 1257. As shown in
the inset, m/z 620 and 659 could be assigned as [permethylated NeuAc-Hex + Na]+ and [permetylated NeuAc-HexNac-ol+Na]+.
334 M.K. Kaneko et al. / FEBS Letters 581 (2007) 331–336and a glycopeptide consisting of Ala23–Glu57 was obtained, in
which four potential Asp-N digestion sites were missed. The
sequencing gap was observed at only Thr52 during Edman
degradation from Ala23 to Glu57 (Fig. 4). Other possible O-
glycosylation sites, such as Thr32, Thr34, and Thr55 (not23 ASTGQP EDDTETTG L EGGV
PLAG1 PLAG
34T Th
r32T Th
r
Fig. 4. Determination of glycosylation site of podoplanin. Amino acid sequen
chromatographs of Asp-N digested hPod/CHO protein. Glycosylated Thr52
obtained using hPod/LN319 protein.shown for others) gave the correct sequences. Therefore, only
Thr52 was O-glycosylated in this peptide. Furthermore, we
conﬁrmed using undigested hPod/LN319 and hPod/CHO pro-
teins that Ala23 was the N-terminal amino acid of both endog-
enous and recombinant podoplanin (data not shown).(52T)
AMPG A EDDVVTPG TSE 57
2 PLAG3
52T
55T
ce of a glycopeptide consisting of Ala23–Glu57 and Edman sequencing
appeared as a gap during peptide sequencing. The same results were
M.K. Kaneko et al. / FEBS Letters 581 (2007) 331–336 335The MS spectrum of the glycopeptide (Ala23–Glu57)
showed a signal with m/z 4367 that was assigned as [Ala23–
GLu57 + (NeuAc)2HexHexNAc-H]
. The glycan structure of
this glycopeptide was characterized as disialyl-corel structure
by tandem mass spectrometry, using the same method
described above (data not shown). Taken together, these data
provided more convincing evidence that the sialyl-corel on the
PLAG domain (Thr52) was critical for platelet aggregation-
inducing activity.3.5. Sialylation of functional podoplanin
Human podoplanin-transfected Lec2 cells could not induce
platelet aggregation [14]. We puriﬁed podoplanin (hPod/Lec2)
from podoplanin-transfected Lec2 (Fig. 1A). As shown in
Fig. 1B, puriﬁed and concentrated hPod/Lec2 induced platelet
aggregation, although podoplanin-transfected Lec2 cells did
not induce aggregation due to its low concentration on these
cell surfaces. Likewise, extremely low concentration of puriﬁed
hPod/Lec2 did not induce platelet aggregation (Fig. 5). Sialic
acid was added to hPod/Lec2 protein using recombinant
sialyltransferases. Fig. 5 shows the recovery of platelet
aggregation-inducing activity of hPod/Lec2 + ST3GalT
(monosialyl-corel), or hPod/Lec2 + ST3GalT + ST6GalNAcT
(disialyl-corel) in spite of their extremely low concentration.
Western-blot analysis showed that sialylated hPod/Lec2
proteins were not degraded (data not shown). These results
conﬁrmed that sialic acid on podoplanin is critical for its plate-
let-aggregating activity.
In summary, we have clariﬁed the glycan structure of human
podoplanin, which is important for its platelet-aggregating
activity; the disialyl-corel is linked to a glycosylation site at
Thr52 in the PLAG domain of podoplanin. Further investiga-
tion is needed to identify the minimum unit of the platelet-acti-
vating glycopeptide within podoplanin. We are investigating
the target molecule for podoplanin on the platelet membrane.
However, the receptor of podoplanin has not been identiﬁed0
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Fig. 5. Recovery of platelet aggregation aggregation-inducing activity.
hPod/Lec2 was used as the acceptor substrate for sialylation. hPod/
Lec2 + ST3GalT (black circle) means sialyl-corel (NeuAca2–3Galb1–
3GalNAca1-) on hPod/Lec2; hPod/Lec2 + ST3GalT + ST6GalNAcT
(red square) means disialyl-corel (NeuAca2–3Galb1–3(NeuAca2–
6)GalNAca1-) on hPod/Lec2. hPod/Lec2 (green triangle) was treated
in the same experimental condition without ST3GalT and ST6GalN-
AcT. Platelet aggregation was measured using WBA Carna with the
screen ﬁltration pressure method. (For interpretation of the references
in colour in this ﬁgure legend, the reader is referred to the web version
of this article.)yet. The results may be exploited to develop new anti-coagu-
lant therapies.
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